Exelixis R&D Chief Says XL647 Could Become “Best-in-Class” EGFR Inhibitor for NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
R&D President Morrissey tells “The Pink Sheet” DAILY that ‘647 could have advantages over other NSCLC treatments like Tarceva and Avastin.